225 related articles for article (PubMed ID: 35669992)
1. Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report.
Pop SR; Strock D; Smith RJ
Dermatol Ther; 2022 Aug; 35(8):e15623. PubMed ID: 35669992
[No Abstract] [Full Text] [Related]
2. Intravenous immunoglobulin for pembrolizumab-induced bullous pemphigoid-like eruption: A case report.
Hoshina D; Hotta M
Dermatol Ther; 2022 Dec; 35(12):e15948. PubMed ID: 36259246
[No Abstract] [Full Text] [Related]
3. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
Cosimati A; Rossi L; Didona D; Forcella C; Didona B
J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 positive macrophages were increased in a case of pembrolizumab-induced bullous pemphigoid.
Nakai K; Sato Y; Kubo S; Tsuruta D
J Dermatol; 2021 Mar; 48(3):e146-e148. PubMed ID: 33439513
[No Abstract] [Full Text] [Related]
5. Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid.
Zhang X; Sui D; Wang D; Zhang L; Wang R
Front Immunol; 2021; 12():731774. PubMed ID: 34594337
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
Klepper EM; Robinson HN
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
[TBL] [Abstract][Full Text] [Related]
7. A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis.
Wang G; Hu X; Han S; Zhou M
J Dermatolog Treat; 2024 Dec; 35(1):2366535. PubMed ID: 38945532
[No Abstract] [Full Text] [Related]
8. Exacerbation of clinical manifestations of bullous pemphigoid after treatment with dupilumab.
Mariotti EB; Corrà A; Aimo C; Ruffo di Calabria V; Quintarelli L; Verdelli A; Caproni M
Clin Exp Dermatol; 2024 Mar; 49(4):399-400. PubMed ID: 38011325
[No Abstract] [Full Text] [Related]
9. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment.
Shipman WD; Singh K; Cohen JM; Leventhal J; Damsky W; Tomayko MM
Br J Dermatol; 2023 Aug; 189(3):339-341. PubMed ID: 37140007
[No Abstract] [Full Text] [Related]
10. Case report: Dupilumab for the treatment of bullous pemphigoid.
Wang M; Wang J; Shi B
Dermatol Ther; 2022 Jul; 35(7):e15541. PubMed ID: 35478478
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.
Seyed Jafari SM; Feldmeyer L; Bossart S; Simon D; Schlapbach C; Borradori L
Front Immunol; 2020; 11():611549. PubMed ID: 33584689
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of checkpoint inhibitor-associated bullous pemphigoid with dupilumab in a patient with angiosarcoma.
Hansen I; Gebhardt C; Booken N; Schneider SW
J Dtsch Dermatol Ges; 2024 Apr; 22(4):587-589. PubMed ID: 38379256
[No Abstract] [Full Text] [Related]
13. Pembrolizumab-Induced Bullous Pemphigoid Treated With Rituximab.
Sharma P; Barnes M; Nabeel S; LiPera W
JCO Oncol Pract; 2020 Nov; 16(11):764-766. PubMed ID: 32716760
[No Abstract] [Full Text] [Related]
14. Pembrolizumab-induced reactivation of bullous pemphigoid.
Kaul S; Wang A; Grushchak S; Albrecht J
Int J Dermatol; 2021 Jun; 60(6):757-758. PubMed ID: 33615441
[No Abstract] [Full Text] [Related]
15. Self-resolving bullous pemphigoid induced by cemiplimab.
Molle MF; Capurro N; Herzum A; Micalizzi C; Cozzani E; Parodi A
Dermatol Ther; 2022 Jun; 35(6):e15466. PubMed ID: 35320611
[No Abstract] [Full Text] [Related]
16. A case of atezolizumab-induced photodistributed bullous pemphigoid.
Leavitt E; Holland V
Dermatol Ther; 2019 Jul; 32(4):e12924. PubMed ID: 30977954
[TBL] [Abstract][Full Text] [Related]
17. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Aggarwal P
Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
[No Abstract] [Full Text] [Related]
18. A case of bullous pemphigoid developing after ixekizumab therapy for pityriasis rubra pilaris.
Sugihara N; Kamiya K; Nakano N; Suzuki M; Maekawa T; Murata S; Komine M; Ohtsuki M
J Dermatol; 2023 Jun; 50(6):e185-e186. PubMed ID: 36651010
[No Abstract] [Full Text] [Related]
19. Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab.
Adachi E; Honda T; Nonoyama S; Irie H; Yamamura K; Otsuka A; Kabashima K
J Dermatol; 2019 Jul; 46(7):e232-e233. PubMed ID: 30758879
[No Abstract] [Full Text] [Related]
20. [Bullous pemphigoid induced by cancer immunotherapy].
Giroud S; Chiticariu-Durr E
Rev Med Suisse; 2020 Apr; 16(688):624-628. PubMed ID: 32239835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
